Industry
"Replace 7OH With Akuammine." The Substitution Is Being Sold In Writing, And Its Central Claim Is Contradicted By The Published Science.

A wholesale flyer reviewed by this publication carries the instruction "REPLACE 7OH WITH AKUAMMINE" across the top, above the words "Stronger. Cleaner. Natural." It offers bulk quantities only, and it is aimed at the people who stock shelves rather than at the people who buy from them.
Two weeks after the Drug Enforcement Administration placed three manufactured kratom derivatives into Schedule I, the replacement for the compound those derivatives were built around is being marketed to retailers in writing, by name, with a comparison table.
The first word of that pitch is the one the published research does not support.
What The Flyer Says
The akuammine flyer sets out a side by side comparison of 7-hydroxymitragynine and akuammine, and attributes to akuammine a set of consumer effects including mood, focus and relaxation, and what it calls a smooth, clean experience. It is offered as bulk wholesale only.
Those are the seller's claims about a product the seller is selling. No regulator has evaluated any of them. This publication reports that the claims were made and does not adopt them, repeat them as fact, or treat them as information about what akuammine does to anyone.
The flyer also carries a private individual's name, email address and telephone number. Those are withheld here. The document is described as a wholesale flyer reviewed by this publication because that is what it is, and because identifying a private seller is not necessary to report the pattern.
A second set of marketing material, from a different product line, sells chewable tablets described as cat's claw extract. That material lists candy style flavours, marks the products 21 and over, advertises a retail price under ten dollars for eight servings, and states that pre-orders are being taken. Across the top it carries three denials in sequence: no 7-OH, no MGM, no kratom. Beneath that it asserts the product is one hundred per cent legal in fifty states.
The Selling Point Is The Statute, Not The Compound
Read together, the two pitches say the same thing in different words, and it is worth stating plainly what that thing is.
Neither flyer leads with a claim that the new compound is better than the old one at anything a chemist would recognise. They lead with what the new compound is not. One is not 7-OH. One is not 7-OH, not MGM, and not kratom. The affirmative claim in both cases is legal availability, and in the second case that claim is made as a number: fifty states.
This publication has reported that structure before, twice. The history of the loophole molecule traced how the Spice era worked, where a scheduled compound was followed within months by a successor marketed on the strength of not being the scheduled one. The report from the CHAMPS floor recorded the same behaviour at trade show scale in August, as booths that had been selling one category of product turned over to another.
What is different here is documentation. This is not an inference from what disappeared off a show floor. It is the pitch itself, in writing, naming the compound it replaces.
Where Akuammine Actually Sits
Akuammine is an indole alkaloid found in the seeds of Picralima nitida, a West African tree with no botanical relationship to kratom. That distance is the entire regulatory position.
The DEA's August 26 order named mitragynine pseudoindoxyl, MGM-15 and MGM-16. The pending threshold order is written against Mitragyna speciosa material and 7-OH content. State Kratom Consumer Protection Acts regulate kratom. None of those instruments describes a different plant in a different family, so none of them reaches akuammine, and this publication has found no state that has moved against it.
Whether that supports the flyer's fifty state assertion is a separate question this report does not answer. Federal scheduling is one layer. States and municipalities regulate on their own timetables, several have broad provisions covering novel or analogous substances, and the Council reported this week that city ordinances have begun reaching conduct no federal or state action touches. A claim that something is legal everywhere is a claim about fifty separate bodies of law, and it is reported here as the seller's assertion.
"Stronger" Is The Part That Does Not Survive Contact With The Literature
The published pharmacology of the akuamma alkaloids is small but consistent, and it points away from the flyer.
Work published in the European Journal of Pharmacology in 1998 by Menzies and colleagues assayed five alkaloids from Picralima nitida seeds. Akuammine, the most abundant of them and the one named on the flyer, showed its highest affinity at mu-opioid binding sites but behaved as an antagonist there rather than an agonist. The authors concluded the group possessed neither high affinity nor selectivity at any opioid receptor.
A 2020 paper in the Journal of Natural Products by Creed and colleagues isolated six akuamma alkaloids and screened them against more than forty central nervous system receptors. Three showed micromolar activity at the mu receptor. Tested for analgesic properties, the authors report they demonstrated limited efficacy, and state that their findings contradict previous reports of the antinociceptive properties of these alkaloids and the traditional use of akuamma seeds as analgesics.
A 2023 paper in the Journal of Medicinal Chemistry describes akuammine as a weak agonist of the mu receptor producing minimal effects in animal models.
Set against a flyer whose first claim is "Stronger," that record is the story. The researchers who have looked hardest at these alkaloids have published that they are weak, and have said in print that the traditional reputation the marketing borrows from is not supported by their data.
This publication makes no claim about what akuammine does in a person, and none of the above should be read as safety information in either direction. The point is narrower and it is about advertising: the central assertion in the pitch is the one the literature most directly contradicts.
What This Report Does Not Establish
Nothing here alleges that any product contains anything other than what its label states. This publication has seen no certificate of analysis, no laboratory result, no warning letter and no enforcement action concerning any of the products described, and does not assert that any of them is adulterated, mislabelled or unlawful. The cat's claw marketing denies the presence of 7-OH, MGM compounds and kratom, and that denial is reported as the seller's own statement rather than contested.
No company is named. The products are described from their own marketing material because the marketing is the evidence, and naming a private seller or a live brand is not necessary to establish that the pitch exists.
Nothing here is a position on whether prohibition of kratom leaf causes substitution. That argument is being made by others, including trade associations and state officials, and it is worth reporting as theirs when they make it. The Kratom Council does not run advocacy campaigns and is not making that case here.
This report describes marketing material and published research. It does not describe any consumer's experience, any clinical outcome, or any regulator's view, because on this compound there is not yet a regulator's view to describe.
Sources
- Wholesale marketing material reviewed by The Kratom Council, September 2026. Identifying details of the private sellers are withheld.
- Menzies JR, Paterson SJ, Duwiejua M, Corbett AD — "Opioid activity of alkaloids extracted from Picralima nitida," European Journal of Pharmacology 350(1):101-8 (1998)
- Creed SM, Gutridge AM, Argade MD, Hennessy MR, Friesen JB, Pauli GF, van Rijn RM, Riley AP — "Isolation and Pharmacological Characterization of Six Opioidergic Alkaloids," Journal of Natural Products 84(1):71-80 (2020)
- Hennessy MR et al. — "Modified Akuamma Alkaloids with Increased Potency at the Mu-opioid Receptor," Journal of Medicinal Chemistry 66(5):3312-3326 (2023)
- Federal Register — temporary scheduling order, mitragynine pseudoindoxyl, MGM-15 and MGM-16, Docket No. DEA-1644 (effective August 26, 2026)
- Federal Register — DEA notice of intent, 7-hydroxymitragynine above a specified threshold, Docket No. DEA-1570 (July 6, 2026)
- The Kratom Council — "Cities Keep Writing Their Own Kratom Rules While The Federal Order Waits" (July 27, 2026)
Get new reporting by email
Federal and state kratom policy, enforcement actions and court decisions — sent when we publish, and nothing else.
The Kratom Council does not sell kratom. This list is used only to send our own articles — never product marketing, and it is never shared with or merged into any retailer’s mailing list. Unsubscribe any time.
